Merz, Maximilian http://orcid.org/0000-0002-2805-5973
Merz, Almuth Maria Anni
Wang, Jie
Wei, Lei http://orcid.org/0000-0002-1881-8666
Hu, Qiang http://orcid.org/0000-0002-4090-5539
Hutson, Nicholas
Rondeau, Cherie
Celotto, Kimberly
Belal, Ahmed
Alberico, Ronald
Block, AnneMarie W.
Mohammadpour, Hemn
Wallace, Paul K.
Tario, Joseph
Luce, Jesse
Glenn, Sean T.
Singh, Prashant
Herr, Megan M. http://orcid.org/0000-0001-5768-9396
Hahn, Theresa http://orcid.org/0000-0002-3835-8855
Samur, Mehmet http://orcid.org/0000-0002-9978-5682
Munshi, Nikhil http://orcid.org/0000-0002-7344-9795
Liu, Song
McCarthy, Philip L.
Hillengass, Jens http://orcid.org/0000-0002-1778-0010
Funding for this research was provided by:
Deutsche Krebshilfe (Mildred Scheel grant)
Article History
Received: 13 January 2021
Accepted: 14 January 2022
First Online: 10 February 2022
Competing interests
: P.L.M.: Advisory Board/Consulting: BlueBird Biotech, Bristol-Myers Squibb, Celgene, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Sanofi, Takeda; Honoraria: BlueBird Biotech, Bristol-Myers Squibb, Celgene, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Sanofi, Takeda. JH: Advisory Boards/ Honoraria: Adaptive, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Oncotracker, Oncopeptide, Skyline, Takeda. M.M.: Advisory Boards/ Honoraria: Amgen, BMS, Celgene and Takeda. Institutional Research Support: Celgene to P.L.M. and M.M. The remaining authors declare no conflict of interest.